CLINICAL TRIALS PROFILE FOR LATREPIRDINE
✉ Email this page to a colleague
Clinical Trials for Latrepirdine
| Trial ID | Title | Status | Sponsor | Phase | Summary |
|---|---|---|---|---|---|
| NCT00912288 ↗ | A Phase 3 Efficacy Study Of Dimebon In Patients With Moderate To Severe Alzheimer's Disease | Terminated | Medivation, Inc. | Phase 3 | No Dimebon clinical data exist yet in patients with disease that has advanced to the moderate-to-severe stage. Therefore, this study evaluates the safety and efficacy of Dimebon in patients with moderate-to-severe AD who are receiving existing background therapy with memantine. |
| NCT00912288 ↗ | A Phase 3 Efficacy Study Of Dimebon In Patients With Moderate To Severe Alzheimer's Disease | Terminated | Pfizer | Phase 3 | No Dimebon clinical data exist yet in patients with disease that has advanced to the moderate-to-severe stage. Therefore, this study evaluates the safety and efficacy of Dimebon in patients with moderate-to-severe AD who are receiving existing background therapy with memantine. |
| NCT00954590 ↗ | A Safety and Efficacy Study Evaluating Dimebon (Latrepirdine) in Patients With Moderate to Severe Alzheimer's Disease | Terminated | Pfizer | Phase 3 | The purpose of this study is to determine if Dimebon is safe and effective in patients with moderate to severe Alzheimer's disease. |
| NCT00954590 ↗ | A Safety and Efficacy Study Evaluating Dimebon (Latrepirdine) in Patients With Moderate to Severe Alzheimer's Disease | Terminated | Medivation, Inc. | Phase 3 | The purpose of this study is to determine if Dimebon is safe and effective in patients with moderate to severe Alzheimer's disease. |
| NCT00975481 ↗ | A Study To Evaluate The Abuse Potential Of Single Oral Doses Of Dimebon (Latrepirdine) In Healthy Recreational Polydrug Users | Completed | Medivation, Inc. | Phase 1 | Dimebon will not exhibit abuse potential when compared to placebo or a positive control (alprazolam). |
| NCT00975481 ↗ | A Study To Evaluate The Abuse Potential Of Single Oral Doses Of Dimebon (Latrepirdine) In Healthy Recreational Polydrug Users | Completed | Pfizer | Phase 1 | Dimebon will not exhibit abuse potential when compared to placebo or a positive control (alprazolam). |
| NCT00988624 ↗ | A Study In Healthy Volunteers To Estimate The Pharmacokinetics Of Four Modified-Release Formulations Of Dimebon (Latrepirdine) | Completed | Medivation, Inc. | Phase 1 | This study will evaluate four different modified release formulation to estimate the amount of dimebon available to the body relative to the current dimebon formulation that is given three times a day. The results of this study will help inform and guide further formulation development efforts with the ultimate goal of reducing dose frequency to once-a-day or twice-a-day. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for Latrepirdine
Condition Name
Clinical Trial Locations for Latrepirdine
Trials by Country
Clinical Trial Progress for Latrepirdine
Clinical Trial Phase
Clinical Trial Sponsors for Latrepirdine
Sponsor Name
